There was a minimal IL-22+CD4+ T-cell and IL-22+γδ T-cell response, but the response of IL-22+CD4+ T cells in BLM/NT127-treated mice was higher (~0.81% CD4+ T cells) than that in BLM-treated mice (~0.034% CD4+ T cells) or NT127-infected mice (~0.14% CD4+ T cells) (Figure S6). The gene discussed is IL22; the disease is Bloom syndrome.